METHODS

Design:

randomised controlled trial.

Allocation:

{concealed*}.†

Blinding:

blinded {patients, clinicians, data collectors, outcome assessors, and data analysts}†.*

Follow up period:

12 months.

Setting:

31 sites in the US.

Patients:

692 patients who were ⩾50 years of age (mean age 76 y, 53% women), met standard research criteria for possible or probable AD, had mild or moderate dementia (Mini-Mental State Examination [MMSE] score 14–26 and a Clinical Dementia Rating [CDR] global score no worse than moderate dementia), and had a reliable informant or caregiver to accompany them to clinic visits and ensure that they …